查看文章

In a long‐term (10‐year) study of radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) as bridging therapy in patients listed for orthotopic liver transplantation (LT), we evaluated the impact of RFA on waiting list dropout rate, post‐LT tumor recurrence, and long‐term intention‐to‐treat, disease‐specific survival (DSS). From March 2004 to October 2014, RFA was performed as the initial stand‐alone bridge therapy to LT for 121 patients (men/women ratio, 83: 38; mean age, 60.0 years) with 156 de novo HCCs (mean size, 2.4 cm). Follow‐up period from initial RFA ranged from 1.3 to 128.0 months (median, 42.9 months). We assessed the overall and tumor‐specific waiting list dropout rates, post‐LT tumor recurrence, and 10‐year post‐LT and intention‐to‐treat survival rates. Dropout from the waiting list due to tumor progression occurred in 7.4% of patients. HCC recurrence after LT occurred in 5.6% of …